Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2013 01:05 ET | Source: Algeta ASA

Algeta ASA : Algeta Results for the Third Quarter 2013

OSLO, Norway, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Intended for US media only Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results...
November 05, 2013 01:06 ET | Source: Algeta ASA

Algeta to Participate in Upcoming Investor Conferences

OSLO, Norway, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its executive management...
October 31, 2013 03:06 ET | Source: Algeta ASA

Algeta ASA : Net Sales of Xofigo (radium Ra 223 dichloride) Injection for Third Quarter 2013

OSLO, Norway, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Intended for US media only Algeta ASA (OSE: ALGETA) announces that Bayer, in its third quarter 2013 results presented today, disclosed that US net...
October 28, 2013 02:08 ET | Source: Algeta ASA

Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call

OSLO, Norway, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its third quarter 2013 results on...
September 20, 2013 08:24 ET | Source: Algeta ASA

Algeta ASA : Xofigo(r) (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union

Intended for US media only OSLO, Norway, Sept. 20, 2013 (GLOBE NEWSWIRE) -- Algeta ASA (OSE: ALGETA), announced today that Bayer has received a positive opinion from the European Medicines...
September 12, 2013 04:18 ET | Source: Algeta ASA

New data and analyses from the phase III ALSYMPCA trial of Xofigo(R) (radium Ra 223 dichloride) injection to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013

OSLO, Norway, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Intended for US media only Algeta ASA (OSE:ALGETA), announced today that further analyses of data subsets from the phase III ALSYMPCA study of...